Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 486-495

  Ravaud, Alain ^a   Urva, Shweta R ^b   Grosch, Kai ^b   Cheung, Wing K ^b   Anak, Oezlem ^b   Sellami, Dalila B ^b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer; Efficacy; Everolimus; Pharmacokinetics; Safety

Indexed keywords

CYTOCHROME P450 3A4; EVEROLIMUS; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER GRADING; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG DISEASE; META ANALYSIS; METABOLIC DISORDER; ONCOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; STEADY STATE; STOMATITIS;

CANCER; EFFICACY; EVEROLIMUS; PHARMACOKINETICS; SAFETY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP3A; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 84893652109     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.11.022     Document Type: Article

References (26)

1. F. Meric-Bernstam, and A.M. Gonzalez-Angulo Targeting the mTOR signaling network for cancer therapy J Clin Oncol 27 2009 2278 2287
2. R.J. Motzer, B. Escudier, and S. Oudard et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
3. J.C. Yao, M.H. Shah, and T. Ito et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
4. M.E. Pavel, J.D. Hainsworth, and E. Baudin et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT 2): a randomised, placebo-controlled, phase 3 study Lancet 378 2011 2005 2012
5. J. Baselga, M. Campone, and M. Piccart et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
6. A.X. Zhu, T.A. Abrams, and R. Miksad et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102
7. T.E. Witzig, C.B. Reeder, and B.R. Laplant et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Leukemia 25 2011 341 347
8. J.C. Soria, F.A. Shepherd, and J.Y. Douillard et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors Ann Oncol 20 2009 1674 1681
9. A. Tarhini, A. Kotsakis, and W. Gooding et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer Clin Cancer Res 16 2010 5900 5907
10. T. Doi, K. Muro, and N. Boku et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer J Clin Oncol 28 2010 1904 1910
11. Afinitor (everolimus) tablets for oral administration [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
12. Afinitor (everolimus) tablets for oral administration [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2013.
13. A. O'Donnell, S. Faivre, and H.A. Burris III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
14. S. Urva, E. Bouillaud, R. Delaney, A. Jappe, and W. Cheung A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects J Clin Pharmacol 53 2013 444 450
15. J. Tabernero, F. Rojo, and E. Calvo et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 2008 1603 1610
16. A. Crowe, A. Bruelisauer, L. Duerr, P. Guntz, and M. Lemaire Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats Drug Metab Dispos 27 1999 627 632
17. W. Jacobsen, N. Serkova, and B. Hausen et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD Transplant Proc 33 2001 514 515
18. J.C. Yao, C. Lombard-Bohas, and E. Baudin et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
20. J.M. Kovarik, D. Beyer, and M.N. Bizot et al. Blood concentrations of everolimus are markedly increased by ketoconazole J Clin Pharmacol 45 2005 514 518
21. J.M. Kovarik, D. Beyer, and M.N. Bizot et al. Effect of multiple-dose erythromycin on everolimus pharmacokinetics Eur J Clin Pharmacol 61 2005 35 38
22. J.M. Kovarik, D. Beyer, and M.N. Bizot et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects Br J Clin Pharmacol 60 2005 434 437
23. J.P. Boni, C. Leister, and G. Bender et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer Clin Pharmacol Ther 77 2005 76 89
24. D.A. Dabydeen, J.P. Jagannathan, and N. Ramaiya et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome Eur J Cancer 48 2012 1519 1524
25. B.J. Atkinson, D.H. Cauley, and C. Ng et al. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes BJU Int 2013 10.1111/bju.12420
26. A. Rinke, H.H. Muller, and C. Schade-Brittinger et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663